Thryv Therapeutics, Inc.
Clinical trials sponsored by Thryv Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Heart condition's hidden toll: new study asks patients about life quality Results expected Dec 2026 (estimated)
- New drug aims to tame dangerous heart rhythms in genetic disorder Results expected Jun 2027 (estimated)
-
New drug aims to tame dangerous heart rhythms in genetic disorder
Disease control Recruiting nowThis study tests whether the drug THRV-1268 can safely shorten the heart's electrical recovery time (QT interval) in people with Long QT Syndrome Type 2, a genetic condition that raises the risk of dangerous heart rhythms and sudden cardiac arrest. About 64 participants will take…
Phase 2/3 • Sponsor: Thryv Therapeutics, Inc. • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Heart condition's hidden toll: new study asks patients about life quality
Knowledge-focused Recruiting nowThis study aims to understand how Long QT Syndrome types 2 and 3 affect the quality of life and daily burden of adults. Researchers will ask up to 200 participants to fill out questionnaires about their physical, emotional, and social well-being. No treatment is given; the goal i…
Sponsor: Thryv Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC